Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AMG0001 in Subjects With Critical Limb Ischemia

NCT02144610 is registered in ClinicalTrials.gov with AnGes USA, Inc. as lead sponsor.

NCT NCT02144610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02144610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AMG0001 in Subjects With Critical Limb Ischemia
Lead sponsor
AnGes USA, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
November 12, 2014
Completion date
November 28, 2016
Enrollment
46 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

critical limb ischemia